The FDA has approved Capvaxive for the prevention of pneumococcal disease in at-risk children and adolescents.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The ACIP vote recommending both vaccines puts the two rivals on a level playing field. While Merck's shot's differentiated coverage will be compelling to purchasers and prescribers, the company still ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of its Capvaxive shot in vulnerable children aged two to 17. While Prevnar – which comes in 13- and 20-valent ...
The U.S. Food and Drug Administration has approved Merck's Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults.
Please provide your email address to receive an email when new articles are posted on . Merck’s 21-valent pneumococcal vaccine Capvaxive was previously approved only for adults. The FDA expanded the ...
Pneumococcal disease is an infection caused by a bacteria called Streptococcus pneumoniae. There are about 100 different types (referred to as serotypes) of pneumococcal bacteria, which can affect ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal ...
CAPVAXIVE elicited immune responses to all 21 serotypes (or strains) as assessed by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 30 days post-vaccination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results